The Joint Corp.
NASDAQ:JYNT · NASDAQ Capital Market
+$0.48 today
Vol 0.04M · Avg 0.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
19.3%
avg -19.9%
ROIC
-3.2%
avg -17.6%
ROA
4.8%
avg -10.0%
Analysis
ROE is currently the strongest return metric at 19.3% versus its period average of -19.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sanjiv Razdan | Chief Executive Officer, President & Director | $1.27M | — | 56 | $162,516.00 | 1.14% |
Scott Justin Bowman | Chief Financial Officer | $514,124.00 | — | 59 | $46,893.00 | 0.33% |
Craig Colmar | Secretary | $37,000.00 | — | 73 | $531,446.00 | 3.73% |
Andra J. Terrell | SVP, Corporate Secretary & General Counsel, | — | — | — | — | — |
Beth Gross | Chief Human Resources Officer | — | — | — | — | — |
Debbie L. Gonzalez | Chief Marketing Officer | — | — | — | — | — |
Charles Nelles | Chief Technology Officer | — | — | — | $1.79M | 12.58% |
Craig Sherwood | SVP & Chief Development Officer | — | — | 59 | $531,446.00 | 3.73% |
Ron Stilwell | Senior Vice President of Operations & Patient Experience | — | — | — | — | — |
Steven Knauf | Vice President of Chiropractic & Compliance | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
18
$2.34M
Sells
0
$0.00
Net Sentiment
+$2.34M
Net buying
Most Active
JOBSON CHARLES E
15 transactions
1–10 of 18
Analysis
Insiders reported 18 buys worth $2.34M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.34M. JOBSON CHARLES E was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +51.0% | +10.6% (11yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +51.0% over three years. Forward estimates point to Revenue at +10.6% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
$220.49M
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
biote Corp.
NASDAQ:BTMD
$108.50M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
CareCloud, Inc.
NASDAQ:CCLD
$97.73M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Sera Prognostics, Inc.
NASDAQ:SERA
$71.42M
DocGo Inc.
NASDAQ:DCGO
$57.25M
SkyAI, Inc.
NASDAQ:STSS
$47.61M
Who manages JYNT?
The Joint Corp. (JYNT) lists 10 active executives. The top listed executive is Sanjiv Razdan, Chief Executive Officer, President & Director.
Are JYNT insiders buying or selling?
Recent insider activity shows net selling of $13.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.